Generic Name and Formulations:
Alprostadil 20mcg, 40mcg; per vial; lyophilized pwd for intracavernous inj after reconstitution; contains benzyl alcohol.
Indications for CAVERJECT:
Treatment of erectile dysfunction. Adjunct to other diagnostic tests in the diagnosis of erectile dysfunction.
Inject into the dorso-lateral aspect in the proximal third of penis, avoid visible veins; rotate inj side and site. Determine optimum dose and give 1st injections in office. Use lowest effective dose. Vasculogenic, psychogenic, or mixed etiology: initially 2.5mcg; if partial response, may increase dose to 5mcg within 1hr; during titration: max 2 doses within 24hr period; if more titration is needed, may give in increments of 5–10mcg at least 24hrs apart until optimal dose is achieved. Usual max: 60mcg. Neurogenic etiology: initially 1.25mcg; if partial response, may increase dose to 2.5mcg within 1hr; during titration: max 2 doses within 24hr period; if more titration is needed, may give 5mcg during the next 24hrs; thereafter, may give doses in increments of 5mcg at least 24hrs apart until optimal dose is achieved. Usual max: 60mcg. Maintenance for home use: max 3 injections/week; allow at least 24hrs between doses. Adjunct in diagnosis: see full labeling.
Predisposition to priapism (eg, sickle cell anemia or trait, multiple myeloma, leukemia). Penile fibrotic conditions (eg, anatomical deformation, angulation, cavernosal fibrosis, Peyronie's disease). Penile implants. Females.
Preexisting cardiovascular disease. Evaluate and treat underlying causes prior to initiating therapy. Treat priapism immediately. Patient must not adjust dose on own. Reevaluate every 3 months. Hypotension; avoid in those with known cavernosa venous leakage. Monitor for signs of penile fibrosis. Discontinue if penile angulation or cavernosal fibrosis develops. Risk of needle breakage; use proper handling and injection techniques. Does not protect against sexually transmitted diseases.
Concomitant vasoactive agents: not established. Concomitant with anticoagulants may increase inj site bleeding.
Penile pain, prolonged erection, penile fibrosis, inj site hematoma or ecchymosis, penis disorder, penile rash or edema, other local effects, dizziness.
Single-dose vials—6; Caverject Impulse 10mcg, 20mcg—2 (dual chamber syringe systems + supplies)
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Adjunctive Therapies for Bipolar Disorder Show Promise, Need More Evidence
- Improving Performance of Everyday Activities Is Critical in Schizophrenia
- Analysis Finds Lithium Maintenance Most Effective as Monotherapy in Bipolar Disorder
- Web-Based Intervention Targets Parental Behaviors That May Affect Adolescent Anxiety, Depression
- Abnormalities of Cortical Thickness in Bipolar Disorder With Auditory Hallucinations
- The Way to the Head May Be Through the Gut: Probiotics for Depression
- Suicide-Screening Toolkit Can Help Identify Youths at High Risk for Suicide
- Agoraphobia: An Evolving Understanding of Definitions and Treatment
- Parental Pressure to Diet Linked With Long-term Harm in Adolescents
- Does Access to Medical Cannabis Reduce Risk for Opioid Abuse?
- Antidepressants Increase Seizure Risk in Youth and Severely Depressed
- Examining Associations Between Diabetes and Effects on Cognition
- Untreated Depression Common in Women of Childbearing Age
- Incidence of Psychiatric Disorders in Rheumatoid Arthritis
- Effect of Antidepressant Class, Dose on Pediatric Anxiety Disorders